IndraLab
Statements
reach
"After the review of the literature and our retrospective examination of 20 lesions, we observed three common and constant components, more or less present in all varieties of TSC cutaneous hamartomas (AF, SP, FCP and FCCH):-abundant thickened collagen, associated with adnexal involvement (concentric fibrosis)-vascular hyperplasia,-cellular proliferation of fibroblasts.TSC1 or TSC2 mutations cause a defect in mTOR inhibition and promote cell proliferation but also angiogenesis and vessel modification due to increased production of VEGF by fibroblastic cells carrying the mutation [3,29]."
reach
"Here, we report that in rat embryonic fibroblasts, activation of mammalian target of rapamycin complex 1 by a Tsc2 mutation or overexpression of a constitutively active mutant Rheb overrides the absence of the anchorage and stabilizes Cdc6 at least partly via activating Cdk4/6 that induces Emi1, an APC/C (Cdh1) ubiquitin ligase inhibitor."
reach
"In this regard, LKB1 mediated AMPK activation leads to accumulation of phosphorylated TSC2 [XREF_BIBR], which inhibits mTOR signaling by blocking phosphorylation of its two key translational regulators, p70 ribosomal S6 kinase 1 (S6K) and eukaryote initiation factor 4E binding protein 1 (4E-BP1) (XREF_FIG) [XREF_BIBR, XREF_BIBR]."
"TSC2 S1798A mutant.Thi s mutant was used to prove that RSK-dependent phosphorylation of tuberin on Ser1798 inhibits its potential to turn off Rheb and to downregulate the activities of mTOR and p70S6K.Mu tation of Ser1798 inhibited most of tuberin phosphorylation and inactivation by RSK (Roux et al., 2004).Invest igating PARP cleavage, caspase 3 cleavage, the percentage of HOPI-positive cells and the percentage of subG1 cells demonstrated that the cell survival effects of activated Ras over tuberin-induced apoptosis are significantly diminished by this mutation in TSC2 (Figures 5a–c)."
reach
"Therefore, in both assays, the TSC2 I820del and L1511H variants were unable to inhibit mTOR, indicating that both these variants are pathogenic, while the TSC2 R1772C and T993M variants were just as active as wild-type TSC2 and are therefore not pathogenic amino acid substitutions."